Vofatamab

CAS No. 1312305-12-6

Vofatamab( —— )

Catalog No. M36756 CAS No. 1312305-12-6

Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 515 Get Quote
5MG 812 Get Quote
10MG 1302 Get Quote
25MG 1822 Get Quote
50MG 2512 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Vofatamab
  • Note
    Research use only, not for human use.
  • Brief Description
    Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
  • Description
    Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    FGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1312305-12-6
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Andrea Necchi, et al. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology 2019 37:7_suppl, 409-409.
molnova catalog
related products
  • FGFR4-IN-1

    FGFR4-IN-1 is a potent FGFR4 inhibitor (IC50: 0.7 nM).

  • TAS120

    TAS-120 is a novel potent and highly selective FGFR inhibitor used for antitumor treatment.

  • Pemigatinib (INCB054...

    Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.